{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341805,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.phrs.2016.01.002","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T17:33:17Z","timestamp":1452187997000},"page":"22-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["UGT genotyping in belinostat dosing"],"prefix":"10.1016","volume":"105","author":[{"given":"Andrew K.L.","family":"Goey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Figg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.01.002_bib0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0010","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","article-title":"Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised double-blind trial","volume":"14","author":"Wu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.01.002_bib0025","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0030","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0035","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1158\/1078-0432.CCR-10-1122","article-title":"Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk","volume":"16","author":"Hu","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2016.01.002_bib0040","unstructured":"Valeant Pharmaceuticals North America LLC. Drug Label Carac Cream, 0.5%. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/getFile.cfm?setid=6795f2b1-1381-4a4f-ad34-2c28ebd1cfaf&type=pdf&name=6795f2b1-1381-4a4f-ad34-2c28ebd1cfaf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0045","unstructured":"Genentech Full Prescribing Information Xeloda, 2015. Available from: http:\/\/www.gene.com\/download\/pdf\/xeloda_prescribing.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0050","unstructured":"Nordic Pharma Summary of Product Characteristics Teysuno. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001242\/WC500104415.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0055","doi-asserted-by":"crossref","first-page":"e54522","DOI":"10.1371\/journal.pone.0054522","article-title":"Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2016.01.002_bib0060","article-title":"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics and toxicities of belinostat administered by 48\u2009h continuous infusion in patients with cancer","author":"Goey","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0065","article-title":"UGT1A1 genotype-dependent dose adjustment of belinostat using population pharmacokinetic modeling and simulation in patients with small cell lung cancer and other advanced cancers","author":"Peer","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.01.002_bib0070","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2016.01.002_bib0075","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.phrs.2016.01.002_bib0080","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0026-895X(24)13065-9","article-title":"Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium","volume":"54","author":"Strassburg","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0085","doi-asserted-by":"crossref","first-page":"36164","DOI":"10.1074\/jbc.M002180200","article-title":"Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine","volume":"275","author":"Strassburg","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.01.002_bib0090","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0021-9258(17)35280-8","article-title":"Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells","volume":"266","author":"Ritter","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2016.01.002_bib0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/humu.9322","article-title":"Spectrum of UGT1A1 mutations in Crigler\u2013Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation","volume":"25","author":"Servedio","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.phrs.2016.01.002_bib0100","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.01.002_bib0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FPC.0000000000000024","article-title":"PharmGKB summary: very important pharmacogene information for UGT1A1","volume":"24","author":"Barbarino","year":"2014","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.phrs.2016.01.002_bib0110","first-page":"21","article-title":"Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese","volume":"46","author":"Akaba","year":"1998","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.phrs.2016.01.002_bib0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0925-4439(98)00013-1","article-title":"Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert\u2019s syndrome and Crigler\u2013Najjar syndrome type II","volume":"1406","author":"Yamamoto","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2016.01.002_bib0120","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1542\/peds.103.6.1224","article-title":"Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism","volume":"103","author":"Maruo","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.phrs.2016.01.002_bib0125","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00008571-199910000-00006","article-title":"Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates","volume":"9","author":"Hall","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2016.01.002_bib0130","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.01.002_bib0135","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/jhep.2001.24172","article-title":"The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR","volume":"33","author":"Sugatani","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2016.01.002_bib0140","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.2002.6683","article-title":"Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia","volume":"292","author":"Sugatani","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.01.002_bib0145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00008571-200212000-00006","article-title":"Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups","volume":"12","author":"Innocenti","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.phrs.2016.01.002_bib0150","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan","volume":"22","author":"Innocenti","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0155","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","article-title":"Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28","volume":"17","author":"Minami","year":"2007","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.phrs.2016.01.002_bib0160","unstructured":"Spectrum Pharmaceuticals Inc. Full prescribing information Beleodaq. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0165","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1158\/1078-0432.CCR-14-0968","article-title":"A phase I\/II trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in thymic epithelial tumors: a clinical and translational study","volume":"20","author":"Thomas","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2016.01.002_bib0170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10147-008-0821-z","article-title":"UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients","volume":"14","author":"Onoue","year":"2009","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0175","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/jnci\/djm115","article-title":"UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters","volume":"99","author":"Hoskins","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phrs.2016.01.002_bib0180","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2008.19.0314","article-title":"Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil leucovorin, and irinotecan","volume":"27","author":"Cecchin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0185","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clpt.2004.01.010","article-title":"UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer","volume":"75","author":"Sai","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.01.002_bib0190","unstructured":"Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutical Review(s): Axitinib. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202324Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2003-06-2105","article-title":"Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia","volume":"103","author":"Kishi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2016.01.002_bib0200","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2009.03363.x","article-title":"Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics","volume":"67","author":"Trontelj","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0205","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/clpt.2009.12","article-title":"Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms","volume":"85","author":"Wenning","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.01.002_bib0210","unstructured":"Sunovion Pharmaceuticals Inc. BROVANA\u2014arformoterol tartrate solution. Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7134ae7c-6c64-470d-ab4e-81e35413b839."},{"key":"10.1016\/j.phrs.2016.01.002_bib0215","unstructured":"Center for Drug Evaluation and Research. Indacaterol: Clinical Pharmacology and Biopharmaceutics Review(s). In.; 2009."},{"key":"10.1016\/j.phrs.2016.01.002_bib0220","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2016.01.002_bib0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.01.002_bib0230","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2016.01.002_bib0235","unstructured":"GlaxoSmithKline, VOTRIENT (pazopanib) tablets: Highlights of Prescribing Information (2012)."},{"key":"10.1016\/j.phrs.2016.01.002_bib0240","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2016.01.002_bib0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/sj.tpj.6500221","article-title":"A Gilbert\u2019s syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia","volume":"4","author":"Danoff","year":"2004","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.phrs.2016.01.002_bib0250","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/hep.21361","article-title":"Gilbert\u2019s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype","volume":"44","author":"Lankisch","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2016.01.002_bib0255","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.fpc.0000197465.14340.d4","article-title":"Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir","volume":"16","author":"Boyd","year":"2006","journal-title":"Pharmacogenet Genom."},{"key":"10.1016\/j.phrs.2016.01.002_bib0260","unstructured":"Pfizer. Prescribing information Camptosar. Available from: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=533."},{"key":"10.1016\/j.phrs.2016.01.002_bib0265","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","article-title":"Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms","volume":"102","author":"Satoh","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phrs.2016.01.002_bib0270","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1200\/JCO.2014.55.2307","article-title":"Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer","volume":"32","author":"Innocenti","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0275","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/JCO.2009.23.6125","article-title":"Genotype-driven phase I study of irinotecan administered in combination with fluorouracil\/leucovorin in patients with metastatic colorectal cancer","volume":"28","author":"Toffoli","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bjc.2011.206","article-title":"A genotype-directed phase I\u2013IV dose-finding study of irinotecan in combination with fluorouracil\/leucovorin as first-line treatment in advanced colorectal cancer","volume":"105","author":"Marcuello","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2016.01.002_bib0285","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00280-013-2161-6","article-title":"A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer","volume":"71","author":"Kim","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0290","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10637-013-0034-9","article-title":"UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine","volume":"31","author":"Goetz","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.phrs.2016.01.002_bib0295","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2014an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.01.002_bib0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/fcp.12117","article-title":"UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice","volume":"29","author":"Etienne-Grimaldi","year":"2015","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.01.002_bib0305","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2016.01.002_bib0310","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.31.5.589","article-title":"Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1","volume":"31","author":"Watanabe","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2016.01.002_bib0315","unstructured":"Bristol\u2013Myers Squibb Company. Etophos (etoposide phosphate) for Injection. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020457s013lbl.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0320","unstructured":"Novartis Pharmaceuticals Corporation. Drug label ARCAPTA NEOHALER\u2014indacaterol maleate capsule Available from: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f7d013b1-5ee9-4126-8297-9efd9a5a8344."},{"key":"10.1016\/j.phrs.2016.01.002_bib0325","unstructured":"Roche Pharma AG. Summary of Product Characteristics Tarceva Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000618\/WC500033994.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0330","unstructured":"Novartis, Tasigna (nilotinib) capsules: Highlights of Prescribing Information, (2010)."},{"key":"10.1016\/j.phrs.2016.01.002_bib0335","unstructured":"Bayer Pharma AG. Summary of Product Characteristics Stivarga (regorafenib) Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002573\/WC500149164.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0340","unstructured":"Bayer Health Care Pharmaceuticals Inc. Prescribing information STIVARGA (regorafenib). Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203085lbl.pdf."},{"key":"10.1016\/j.phrs.2016.01.002_bib0345","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:24:01Z","timestamp":1748744641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":69,"alternative-id":["S1043661816000037"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.01.002","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UGT genotyping in belinostat dosing","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}